Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.38 USD
-0.17 (-6.67%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $2.39 +0.01 (0.42%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Cellectar Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 20 | 36 | 57 | 11 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 10 | 21 | 37 | 58 | 11 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 12 | 22 | 37 | 59 | 12 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 5 | 4 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 6 | 4 | 4 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 6 | 4 | 4 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 6 | 1 | 1 | 20 | 1 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 210 | 194 | 183 | 162 | 120 |
Retained Earnings | -217 | -180 | -151 | -127 | -112 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -1 | 16 | 33 | 55 | 9 |
Total Liabilities & Shareholder's Equity | 12 | 22 | 37 | 59 | 12 |
Total Common Equity | -7 | 14 | 32 | 35 | 8 |
Shares Outstanding | 20.70 | 9.30 | 6.10 | 4.50 | 0.90 |
Book Value Per Share | -0.36 | 1.52 | 5.19 | 7.72 | 8.79 |
Fiscal Year End for Cellectar Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 40 | 10 | 19 | 5 | 13 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 0 | 1 |
Total Current Assets | 41 | 10 | 20 | 6 | 14 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 43 | 12 | 22 | 7 | 15 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 9 | 8 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 4 | 9 | 0 | 0 |
Total Current Liabilities | 16 | 13 | 16 | 6 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 18 | 0 | 0 |
Total Liabilities | 17 | 13 | 35 | 7 | 8 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 17 | 6 | 1 | 1 | 1 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 248 | 210 | 195 | 194 | 194 |
Retained Earnings | -239 | -217 | -210 | -196 | -188 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 26 | -1 | -13 | 0 | 7 |
Total Liabilities & Shareholder's Equity | 43 | 12 | 22 | 7 | 15 |
Total Common Equity | 9 | -7 | -15 | -2 | 6 |
Shares Outstanding | 35.80 | 20.70 | 9.90 | 9.70 | 9.70 |
Book Value Per Share | 0.25 | -0.36 | -1.49 | -0.19 | 0.61 |